At a glance
A combined research record involving separate TB-500 and BPC-157 vials.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together separate TB-500 and BPC-157 vials. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[1][2][3]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of TB-500 + BPC-157.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg + 5 mg · 2 source tables
TB-500 Protocol (2 mL Reconstitution = 2.5 mg/mL)
| Week | Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–4 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Twice weekly |
| Weeks 5–12 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Once weekly |
Route: Subcutaneous injection. The loading phase (Weeks 1–4) uses twice-weekly dosing to establish tissue saturation, followed by a maintenance phase (Weeks 5–12) at once weekly[1].
BPC-157 Protocol (2 mL Reconstitution = 2.5 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
| Weeks 3–8 | 500 mcg (0.50 mg) | 20 units (0.20 mL) | Once daily |
| Weeks 9–12 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
Route: Subcutaneous injection, preferably near the site of injury. Preclinical research commonly uses 250–500 mcg per day for musculoskeletal applications[3][4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the combined regimen.
- Goal: Support tissue repair, reduce inflammation, and accelerate recovery from musculoskeletal injuries[1][3].
- Schedule: TB-500 twice weekly (loading) then once weekly (maintenance); BPC-157 daily throughout.
- Dose Range: TB-500: 1,250 mcg per injection; BPC-157: 250–500 mcg daily.
- Reconstitution: 2.0 mL per 5 mg vial for both peptides (~2.5 mg/mL).
- Storage: Refrigerate lyophilized and reconstituted solutions; use within ~30 days after reconstitution.
Suggested combined approach for synergistic tissue support.
- TB-500 Loading: 1,250 mcg twice weekly for 4 weeks (total ~2.5 mg/week).
- TB-500 Maintenance: 1,250 mcg once weekly for Weeks 5–12.
- BPC-157 Start: 250 mcg daily for 2 weeks, then increase to 500 mcg daily.
- BPC-157 Taper: Return to 250 mcg daily for final 4 weeks (Weeks 9–12).
- Timing: Inject at consistent times; BPC-157 preferably near injury site.
Preparation
TB-500 Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
BPC-157 Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for long-term storage, −20 °C (−4 °F) is acceptable[9].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~30 days; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7][8].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].
- For BPC-157, injecting near the injury site may enhance local effects[4].
Materials & quantity planning
Source materials checklist · 5 mg + 5 mg
Plan based on an 8–16 week combined protocol with the schedules above.
-
TB-500 Vials (5 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
-
BPC-157 Vials (5 mg each):
- 8 weeks ≈ 5 vials
- 12 weeks ≈ 7 vials
- 16 weeks ≈ 8 vials
-
Insulin Syringes (U-100):
- 8 weeks: 68 syringes (TB-500: 12 + BPC-157: 56)
- 12 weeks: 100 syringes (TB-500: 16 + BPC-157: 84)
- 16 weeks: 132 syringes (TB-500: 20 + BPC-157: 112)
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (8 total vials): 16 mL → 2 × 10 mL bottles
- 12 weeks (11 total vials): 22 mL → 3 × 10 mL bottles
- 16 weeks (13 total vials): 26 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- 8 weeks: ~160 swabs → recommend 2 × 100-count boxes
- 12 weeks: ~232 swabs → recommend 3 × 100-count boxes
- 16 weeks: ~304 swabs → recommend 4 × 100-count boxes
View Supplier
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
Frontiers in Endocrinology (2021) — Progress on the Function and Application of Thymosin β4 (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
Annals of the New York Academy of Sciences — Thymosin β4: roles in development, repair, and engineering of the cardiovascular system (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
Frontiers in Pharmacology (2022) — Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
HSS Journal (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
Current Pharmaceutical Design (2018) — Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
Journal of Orthopaedic Surgery and Research (2019) — BPC 157 and its effects on tendon healing (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
CDC (2024) — Vaccine Administration: Subcutaneous (SUBCUT) Injection (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf (2023) — Administration of Parenteral Medications – Nursing Skills (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.